47 results about "Nonhuman animal" patented technology

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The application provides a construction system and device of a non-human animal model of tension pneumothorax, and the system comprises: a fixing unit for fixing the non-human animal; a first processing unit for puncturing a puncture needle to the parietal pleura, making a guide wire pass through the needle cavity of the puncture needle to enter the pleural cavity, and withdrawing the puncture needle; a second processing unit for inserting a catheter along the guide wire to make the catheter enter the pleural cavity, pulling out the guide wire, and fixing the catheter; a third processing unit for unidirectional air injection into the pleural cavity through the catheter; and a fourth processing unit for monitoring the range of pneumothorax, determining that the non-human animal model of tension pneumothorax is obtained when the lung sliding of the injection side chest is greater than or equal to 4 / 6 area and lung points are observed, stopping air injection, and obtaining the non-human animal model of tension pneumothorax. The construction success rate of the application is 100%, the construction process is rapid, repeatable and objective in determination, and the application can provide a rapid and repeatable platform for diagnostic research, decompression technology evaluation and training.

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

A genetically modified non-human animal in which an auxin-inducible degron system controls degradation of a target protein in a living body includes: a chromosome containing a first nucleic acid that encodes a mutant TIR1 family protein having a mutation at an auxin-binding site and having affinity to an auxin analog.

Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification and characterization of microbiota may include identifying and characterizing the microbiota of potential donors, characterizing the potential donors, and identifying potentially therapeutic microbiota based on analysis of such data from multiple individuals. In some embodiments, the identification and characterization of microbiota may include testing, that is, administering microbiota of potential donors to animals suffering from a disease or condition, documenting any therapeutic response, and optionally identifying and characterizing the microbiota of recipients before and after treatment, and optionally identifying demonstrated therapeutic microbiota. Embodiments of the invention encompass compositions comprising the microbiotia, including solid oral compositions, methods of making these compositions, and methods of treatment of non-human animals suffering from various diseases and conditions with these compositions.

Methods for inducing basal cell carcinoma (BCC) or BCC tumors, as well as an inducible non-human animal models of BCC, are defined herein. The methods and animal models comprise targeting Ptch1 and / or a tumor suppressor gene via conditional expression of one or more short hairpin RNAs (shRNAs) in the skin of said animals.

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.

A nonhuman animal having a chimeric organ including a foreign cell in a body thereof.

A device for indicating entry of a needle into a body cavity, a conduit or a blood vessel of a human or non-human animal has a pressure sensor configured, in use, to be in fluid communication with a pinhole of the needle; and a selectively activated indicator. The device is configured to activate the indicator when a pressure acting on the pressure sensor reaches or is above a minimum pressure threshold, where the minimum pressure threshold is about 25 cmH2O.

Non-human animal cells and non-human animals comprising a humanized Tfrc gene, e.g., at an endogenous Tfrc locus, and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Tfrc gene express a human TfR protein or fragments thereof. Non-human animal cells and non-human animals comprising a humanized Tfrc gene and a knockout mutation in a Gaa gene, e.g., at an endogenous Gaa locus, and methods of using such non-human animal cells and non-human animals are also provided. Such animals are useful to screen anti-human-TfR binding protein based therapies of, e.g., Pompe disease.

To provide non-human animals expressing exogenous terminal deoxynucleotidyltransferase.SOLUTION: Provided herein are methods and compositions relating to non-human animals that express exogenous terminal deoxynucleotidyltransferase (TdT). In certain aspects, provided herein are genetically modified non-human animals that include in their genome an exogenous nucleic acid encoding terminal deoxynucleotidyltransferase (TdT), as well as production and use methods of such non-human animals. In some embodiments, the exogenous TdT is human TdT. In some embodiments, the exogenous TdT is from an endogenous species (eg, in mice, exogenous TdT has a mouse sequence).SELECTED DRAWING: None

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.

A composition including a mixture of extracts of aromatic plants, and in particular extracts of lemon balm, thyme, rosemary, wormwood and lemongrass, veterinary or pharmaceutical compositions including the composition and a food for non-human animals including the composition. Also, a method for preparing the composition and a method for the prevention or treatment of flea infestation that include the administration of the composition to a domestic mammal.

Compositions, assays, methods, diagnostic methods, kits, and diagnostic kits are disclosed for the specific and differential detection of SARS-COV-2 and / or other viruses from samples, including veterinary samples, clinical samples, food samples, forensic sample, environmental samples (e.g., obtained from soil, garbage, sewage, air, water, food processing and manufacturing surfaces, or likewise), or biological sample obtained from a human or non-human animal.

Provided is a non-human animal that is useful for analysis of a kallikrein-kinin system. A non-human animal that lacks the Kng1 gene and the Kng2 gene.

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

The present invention provides a genetically modified non-human animal or the like that functionally lacks an endogenous ABCB1 gene and that functionally expresses the human ABCB1 gene, the genetically modified non-human animal or the like retaining a DNA construct for functionally expressing the human ABCB1 gene, wherein the DNA construct includes a coding sequence for the human ABCB1 gene, a CAR / PXR response element present in the 5' promoter region of the human ABCB1 gene, at least one intron of the human ABCB1 gene, and a sequence of the enhancer region present at the 3' end side of the human ABCB1 gene, and the DNA construct does not include at least a portion of the coding sequence for the human ABCB4 gene or includes only a portion of the human RUNDC3B gene.

Described herein is the discovery that neither the nuclear localization signal (NLS) nor the prion-like domain (PLD) of TDP-43 is necessary for embryonic stem cell culture and differentiation into motor neurons in vitro. The ability of ES cells to express these TDP-43 mutants and differentiate into motor neurons that exhibit an ALS-like phenotype whereby the TDP-43 mutants redistribute to and aggregate in the cytoplasm and fail to regulate cryptic exon splicing allows these cells to act as a model of TDP-43 proteinopathy for the testing of candidate therapeutic agents that may resolve such proteinopathy. Additionally, these ES cells may be used to successfully generate non-human animals, e.g., mice, that also exhibit hallmark symptoms of ALS and that may be used in testing candidate agents useful in treating TDP-43 proteinopathies.

This document relates to non-human animal models (e.g., non-human mammalian models such as mouse models) for aging (e.g., neural aging). For example, non-human animal models having reduced or eliminated levels of aralkylamine N-acetyltransferase (AANAT) polypeptide expression are provided.

Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification and characterization of microbiota may include identifying and characterizing the microbiota of potential donors, characterizing the potential donors, and identifying potentially therapeutic microbiota based on analysis of such data from multiple individuals. In some embodiments, the identification and characterization of microbiota may include testing, that is, administering microbiota of potential donors to animals suffering from a disease or condition, documenting any therapeutic response, and optionally identifying and characterizing the microbiota of recipients before and after treatment, and optionally identifying demonstrated therapeutic microbiota. Embodiments of the invention encompass compositions comprising the microbiotia, including solid oral compositions, methods of making these compositions, and methods of treatment of non-human animals suffering from various diseases and conditions with these compositions.

To provide novel compounds for use in the treatment or prevention of cancer and other proliferative conditions. [Solution] The present invention relates to novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing cytochrome P450 1B1 (CYP1B1) and its allele variants. The present invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapies, for example, in the treatment or prevention of cancer or other proliferative conditions, as well as methods for treating cancer or other conditions in human or non-human animal patients. The present invention also provides methods for identifying novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing CYP1B1 and its allele variants. The present invention also provides methods for determining the efficacy of the compounds of the present invention in cancer treatment.

Genetically modified non-human animals that express a human or chimeric (e.g., humanized)ERBB, and methods of use thereof are disclosed.

A novel antimicrobial agent is provided, and a compound represented by formula (I) or (II) or a salt thereof is used as an antimicrobial agent for a non-human animal.

The present invention relates to a composition for the nutrition or drink of a non-human animal comprising the combination of spirulina and Ascophyllum nodosum. It further relates to the use of this composition for improving the zootechnical performance of non-human animals.

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and / or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.

To provide an animal to be a model of human chronic obstructive pulmonary disease.SOLUTION: A method for producing a non-human animal model of chronic obstructive pulmonary diseases, comprising inducing deletion of Wfdc2 genes by administering an antiestrogen to adult non-human animals which have genes in which at least one exon of CreERT2 is flanked by two loxP sequences in both alleles, which systemically express antiestrogen-dependent recombinant Wfdc2, and which can delete Wfdc2 genes in an antiestrogen-inducible manner. The chronic obstructive pulmonary disease model non-human animal is produced by the method.SELECTED DRAWING: Figure 1